Eli Lilly Bets Nearly $500M on Metabolic Disease Pact with Nimbus
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases
Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases
- Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD,...
Capstan Therapeutics has launched to combine cell therapy and genetic medicines to bring safer medicines to patients in multiple indications.
Press release content from Business Wire. The AP news staff was not involved in its creation.
STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets CAMBRIDGE, England, Sept. 12, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the